Pharmaceutical News

RSS

Some caregivers unsure about when to give epinephrine for children with food allergies

Young children with allergies to milk and egg experience reactions to these and other foods more often than researchers had expected, a study reports. The study also found that severe and potentially life-threatening reactions in a significant number of these children occur and that some caregivers are hesitant to give such children epinephrine, a medication that reverses the symptoms of such reactions and can save lives.

26 Jun 2012

Sunflower peptides can treat itchy skin problems

Sunflowers may hold the solution to a problem which gets under the skin of millions of Australians every year. Skin conditions such as eczema, dermatitis, rosacea and the lesser-known Netherton Syndrome pose an itchy problem for many sufferers world-wide, but a group of researchers from Queensland University of Technology (QUT), in Brisbane Australia, are looking at ways to soothe the problem - with tiny proteins called peptides, found in sunflowers.

26 Jun 2012

Long-term intensive combination lipid therapy may be effective against atherosclerotic disease

For the first time, a study has found that intensive cholesterol therapy involving a combination of drugs for 20 years may be more effective over the long run than taking a single statin medication.

26 Jun 2012

Pfizer, Wyeth and PF Prism file suit against Watson over generic Pristiq

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Desvenlafaxine Succinate Extended-release Tablets, 50 mg and 100 mg.

26 Jun 2012

Merck Serono, Compugen announce establishment of Neviah Genomics

Merck Serono, a division of Merck, Darmstadt, Germany, and Compugen Ltd. today announced the establishment of Neviah Genomics, a novel start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity.

26 Jun 2012

CHRI signs new sales LOI with Pengxi Huitong Pharmaceutical

China Health Resource, Inc., announced today that it has signed a new sales letter of intent (LOI) for this year for its proprietary Yishen Capsule valued at 25 million RMB; approximately $4 million USD.

26 Jun 2012

Three widely used diabetes medications associated with greater risk of death

Compared to another popular drug, three widely used diabetes medications are associated with a greater risk of death, a large new analysis finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

China SFDA approves China Biologic's Human Coagulation Factor VIII

China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. has received a manufacturing approval certificate from the China State Food and Drug Administration for Human Coagulation Factor VIII ("FVIII").

25 Jun 2012

Standard aspirin dose may not protect diabetics against blood clots

Many patients with type 2 diabetes may be aspirin resistant. That means the standard aspirin dose may not protect them against blood clots that cause heart attacks and strokes among diabetics, a new clinical study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

FDA approves Actavis Mixed Amphetamine Salts ER Capsules

Actavis Group, an international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules CII, (hereafter referred to as Mixed Amphetamine Salts ER Capsules), in all available strengths: 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg.

25 Jun 2012

MAP Pharmaceuticals completes End-of-Review meeting with FDA for LEVADEX NDA

MAP Pharmaceuticals, Inc. today announced that the Company completed an End-of-Review meeting with the United States Food and Drug Administration (FDA) for its New Drug Application (NDA) for LEVADEX (dihydroergotamine) inhalation aerosol.

25 Jun 2012

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

Bristol-Myers Squibb Company and Pfizer announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

25 Jun 2012

U.S. District Court rules in favor of Teva in COPAXONE patent infringement case

Teva Pharmaceutical Industries Ltd. announced today the U.S. District Court for the Southern District of New York has found in favor of Teva in the Company's patent infringement lawsuit against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Laboratories Inc./Natco Pharmaceuticals regarding Teva's relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE.

23 Jun 2012

GMCSF linked with rapid cognitive recovery in patients with cancer

Growth factors shown to cure Alzheimer's disease in a mouse model and administered to cancer patients as part of their treatment regimen were linked to significant improvements in the patients' cognitive function following stem cell transplantation, a preliminary clinical study reports.

23 Jun 2012

No definitive link between hormonal contraceptives and increased risk of HIV infection among women, CDC says

"There is no clear link between the use of contraceptives such as the birth control pill or Depo-Provera shots and an increased risk that a woman will contract HIV, the U.S. Centers for Disease Control and Prevention said on Thursday," Reuters reports, noting that the WHO came to the same conclusion in February.

23 Jun 2012

Growing number of countries adopting flexible IP regulations after India issues country's first compulsory license

"A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health," India's Economic Times reports, noting, "In March, India issued the country's first compulsory license, allowing Natco Pharma to legally manufacture and sell a low-cost version of German drugmaker Bayer AG's patented cancer drug, Nexavar, at 3 percent of the original medicine's price on the grounds that Bayer's drug was not meeting public health requirement."

23 Jun 2012

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

Weill Cornell Medical College researchers have devised an innovative boxer-like strategy, based on the serial use of two anti-cancer drugs, to deliver a one-two punch to first weaken the defenses of multiple myeloma and then deliver the final knock-out punch to win the fight.

23 Jun 2012

EMA CHMP adopts positive opinion for Seebri Breezhaler to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Seebri Breezhaler (glycopyrronium/NVA237) 44 mcg delivered dose (50 mcg glycopyrronium per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

23 Jun 2012

FDA issues CRL to Repligen's RG1068 NDA for treatment of pancreatitis

Repligen Corporation today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for RG1068.

23 Jun 2012